Generic Name
Tranexamic acid
Cardiovascular System
Tranexamic acid.........500 mg
Antifibrinolytic agent
Tranex tablet contains tranexamic acid which has a strong inhibitory effect on the activation of plasminogen, i.e. the conversion of plasminogen to plasmin in the fibrinolytic system.
Tranexamic acid is used in episodes of fibrinolytic bleding which may occur in different clinical situations involving stimulation of the activation mechanism.
Local fibrinolysis may occur in the following conditions and situation:
  • Prostatectomy and bladder surgery
  • Hematuria
  • Gastrointestinal hemorrhage
  • Epistaxis
  • Menorrhagia
  • Ulcerative colitis
  • Conization of the cervix
  • Dental extraction in patients with coagulpathies
General fibrinolysis may occur in the following conditions and situations:
  • Prostatic and pancreatic cancer
  • Leukemia
  • After major surgery
  • Liver diseases
  • In obstetric complications
  • In connection with streptokinase thrombolytic therapy
Tranexamic acid is very well absorbed from the gastrointestinal tract, and is excreted in an unchanged form via the kidneys.
Tranex tablet is an antifibrinolytic agent indicated for:
  • Hemorrhage or risk of hemorrhage in increased fibrinolysis or fibrinogenoylsis
  • Hereditary angioneurotic edema
Drug Interactions
Side Effects/Adverse Effects
The following side effects are observed:
  • Gastrointestinal disturbances may occur at an oral administration of 6 gm/day.
  • Nausea, vomiting and dairrhea may occur (>1/100)
  • Color vision disturbances may also occur (<1/1000)
Pregnancy & Lactation
There are no adequate and well-controlled studies in pregnant women.
Tranexamic acid passes into the breast milk, but an adverse effect on the child seems unlikely in the therapeutic dose range.
Dosage & Administration
The recommended standard dose is 2-3 tablets of 500 mg, 2 to 3 times daily.
For the indications listed below, the following doses are recommended:
  • 0.5-1.0 grams orally every 6 to 8 hours for the first3 days after surgery.
  • Thereafter, 1-1.5 grams orally (2-3 tablets), 2 to 3 times daily until macroscopic hematuria disappears.
  • 1-1.5 grams orally (2-3 tablets), 2 to 3 times daily until macroscopic heamturia disappears.
  • 1.5 grams orally (3 tablets), 3 times daily for 4-10 days.
  • 1-1.5 grams orally (2-3 tablets), 3 to 4 times daily for 3-4 days.
  • Tranex is initiated when bleeding hsa become profuse.
Conization of the Cervix
  • 1.5 grams orally (3 tablets), 3 times daily for 12 to 14 days postoperatively.
Hereditary Angioneurotic Edema
  • 1-1.5 grams orally (2-3 tablets), 2-3 times daily as intermittent or continuous treatment, depending on whether the patient hsa prodormal symptoms or not.
In patients with moderately to severely impaired renal function, the following dose modifications are applied.
Serum Creatinine:
  • 120-249 mmol/L: 15 mg/kg twice daily
  • 250-500 mmol/L: 15 mg/kg daily
  • >500 mmol/L: 7.5 mg/kg daily
Caution is needed when Trenax is used in patients with renal insufficiency and in massive hematuria from the upper urinary tract.
Patients with a previous history of thromboembolic disease should not be given Tranex unless simultaneous treatment with anticoagulants can be given.
Store at a temperature not exceeding 30°C in a dry place.
Box of 20 tablets in 2 strips.
Egyptian Group for Pharmaceutical Industries Co.
Date Added/Updated
6th November 2011 2:30 pm


Share This!

Respected Sites

Need Help?

on-call support